Source and scope
This summary is bounded to the recommendations, population and decisions covered by Chlamydia and LGV guide: Treatment and follow-up. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:PHAC chlamydia
Source-attributed clinical priorities
- Use nucleic-acid testing from exposed anatomic sites and assess pregnancy and symptoms of upper-genital or epididymal infection.
- Treat with the current PHAC regimen and account for pregnancy, adherence and possible lymphogranuloma venereum.
- Arrange partner management, abstinence advice, retesting and other STI screening under local public-health requirements.
- Test all exposed sites and treat partners to prevent reinfection.
sources for this section:PHAC chlamydia
Practical assessment and management workflow
1
Ask about anatomic exposure, symptoms, pregnancy, allergy and prior infection.
2
Collect nucleic-acid testing and offer gonorrhea, syphilis and HIV testing as appropriate.
3
Give the current Canadian regimen and communicate abstinence advice until treatment is complete.
4
Arrange partner notification and repeat testing at the recommended interval.
sources for this section:PHAC chlamydia
Safety, red flags and urgent escalation
- Pelvic pain, testicular pain, fever or pregnancy requires complication-aware management.
- Use a pregnancy-compatible regimen and arrange follow-up when indicated.
- Do not use a test of cure too early because residual nucleic acid can remain detectable.
sources for this section:PHAC chlamydia
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:PHAC chlamydia
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:PHAC chlamydia
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Public Health Agency of CanadaChlamydia and LGV guide: Treatment and follow-upaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.